Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Trading 05-11 09:52:11 EDT

334.38

+4.36

+1.32%

High339.23	Low330.02	Vol79.45K
Open330.02	D1 Closing330.02	Amplitude2.79%
Mkt Cap9.31B	Tradable Cap8.62B	Total Shares27.85M
T/O26.72M	T/O Rate0.31%	Tradable Shares25.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":334.38,"timestamp":1778507524902,"preClose":330.02,"halted":0,"volume":79445,"delay":0,"changeRate":0.013211320526028768,"floatShares":25778700,"shares":27850833,"eps":-13.34879,"marketStatus":"Trading","change":4.36,"latestTime":"05-11 09:52:11 EDT","open":330.02,"high":339.23,"low":330.02,"amount":26717297.8885,"amplitude":0.027907,"askPrice":336.94,"askSize":22,"bidPrice":333.89,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-13.34879,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778529600000},"marketStatusCode":2,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":330.02,"preHourTrading":{"tag":"盘前","latestPrice":330,"preClose":330.02,"latestTime":"08:17 EDT","volume":59,"amount":19188.99008,"timestamp":1778501847697,"change":-0.02,"changeRate":-0.000061,"amplitude":0.021181},"postHourTrading":{"tag":"盘后","latestPrice":330.02,"preClose":330.02,"latestTime":"17:40 EDT","volume":5409,"amount":1785152.98,"timestamp":1778276410353,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.472739,"impliedVol":0.6855,"impliedVolPercentile":0.1116},"requestUrl":"/m/hq/s/PRAX/wiki","defaultTab":"wiki","newsList":[{"id":"2633452673","title":"Praxis Precision price target raised to $166 from $130 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633452673?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:50","pubTimestamp":1778248227,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $166 from $130 and keeps an Underperform rating on the shares following quarte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-166-from-130-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-166-from-130-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4139","LU0889565916.HKD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633451399","title":"Wedbush Remains a Sell on Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633451399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633451399?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:58","pubTimestamp":1778245132,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Sell rating on Praxis Precision Medicines, with a price target of $166.00. Chico ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-sell-on-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-sell-on-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","PRAX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145694","title":"Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145694","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145694?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:23","pubTimestamp":1778242999,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of Buy and mean price target of $647.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633458206","title":"Praxis Precision Medicines Inc : Wedbush Raises Target Price to $166 From $130","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458206?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:24","pubTimestamp":1778239471,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L1PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","LU0889565916.HKD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4139","IE00BFTCPJ56.SGD","PRAX","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633302884","title":"Praxis Precision Medicines, Inc.  : Deutsche Bank Cuts Target Price to $420 From $444","url":"https://stock-news.laohu8.com/highlight/detail?id=2633302884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633302884?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:04","pubTimestamp":1778238266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nAQN2LY8BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","PRAX","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943044","title":"H.C. Wainwright Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943044","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943044?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:56","pubTimestamp":1778237816,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $1,245.00. According to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343702","title":"Praxis Precision Med Price Target Maintained With a $843.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633343702?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:50","pubTimestamp":1778237400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 06:50 ET (10:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","PRAX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633837234","title":"Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline and De-Risked Ulixacaltamide NDA Support Unchanged $554 Buy Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2633837234","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633837234?lang=en_us&edition=fundamental","pubTime":"2026-05-08 12:06","pubTimestamp":1778213187,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Praxis Precision Medicines, with a price target of $554.00. Rit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/praxis-therapeutics-advancing-late-stage-neurology-pipeline-and-de-risked-ulixacaltamide-nda-support-unchanged-554-buy-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/praxis-therapeutics-advancing-late-stage-neurology-pipeline-and-de-risked-ulixacaltamide-nda-support-unchanged-554-buy-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","BK4007","PRAX","IE00BJJMRZ35.SGD","SSI","IE0002141913.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4539","BK4139","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0109394709.USD","LENZ","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633815142","title":"Praxis Precision Medicines publishes corporate presentation on CNS pipeline, near-term regulatory catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633815142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633815142?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:20","pubTimestamp":1778156409,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines outlined a late-stage CNS portfolio with two pending FDA decisions, targeting relutrigine action date of Sep. 27, 2026 under Priority Review, followed by ulixacaltamide action date of Jan. 29, 2027.Ulixacaltamide Phase 3 ESSENTIAL3 program in essential tremor showed a Day 56 mADL11 change from baseline of -4.3 versus -1.7 for placebo, with p<0.0001; a randomized-withdrawal study showed 55% maintained response versus 33% on placebo.Relutrigine NDA was accepted for SCN2A- and SCN8A-developmental and epileptic encephalopathies; company also guided to topline EMERALD data in Q4 2026 for broader phenotypic DEEs.Praxis projected portfolio peak sales potential above USD 20 billion, citing ulixacaltamide above USD 10 billion, relutrigine above USD 5 billion, vormatrigine above USD 4 billion; cash runway guided into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3QRxhb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","BK4139","PRAX","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144937","title":"Praxis Precision's Q1 net loss widens on higher expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144937?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:07","pubTimestamp":1778155674,"startTime":"0","endTime":"0","summary":"Praxis Precision's Q1 net loss widens on higher expensesOverviewU.S. CNS biopharma's Q1 net loss widened yr/yr on higher R&D and admin costsCompany's cash and investments rose to $1.4 bln, expected to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE0009355771.USD","PRAX","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144890","title":"Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144890","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144890?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:02","pubTimestamp":1778155361,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.20) per share which beat the analyst consensus estimate of $(3.50) by 8.57 percent. This is a 2.74 percent increase over losses of $(3.29) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52362764/praxis-precision-medicine-q1-eps-3-20-beats-3-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","PRAX","IE00BJJMRZ35.SGD","BK4139","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633715141","title":"BRIEF-Praxis Precision Q1 EPS USD -3.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2633715141","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633715141?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155246,"startTime":"0","endTime":"0","summary":"BRIEF-Praxis Precision Q1 EPS USD -3.2\n\n\nMay 07 (Reuters) - Praxis Precision Q1 operating expenses USD 105.86 million.\n\nQ1 net income USD -92.561 million\nQ1 operating income USD -105.86 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX183E93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","BK4139","PRAX","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141736","title":"Praxis Precision Q1 Operating Income USD -105.86 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141736?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX183E93:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","PRAX","IE0009355771.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141282","title":"Praxis Precision Q1 Net Income USD -92.561 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141282?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX183E93:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRAX","LU0109394709.USD","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410981","title":"Press Release: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410981","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410981?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"FDA accepted the new drug application  for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies  with a PDUFA target action date of September 27, 2026. EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE. Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026. Recruiting completed for relutrigine EMERALD study in broad DEEs, with topline results expected in Q4 2026. Cash and investments of approximately $1.4 billion as of March 31, 2026 maintains runway into 2028. BOSTON, May 07, 2026  -- Praxis Precision Medicines, Inc. , a fully integrated, leading central nervous system  precision neuroscience biopharmaceutical company, today provided a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4178","ET","IE0002141913.USD","BK4139","BK4588","BK4200","03160","CNS","PRAX","BK4555","AAN","IE00B2B36J28.USD","BK4099","BK4604","IE0009355771.USD","BK4581","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4144","TM","BK4135","LU0320765992.SGD","BK4561","BK4590","ASO","LU0109394709.USD","BK4585","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633292560","title":"Praxis Precision Medicines grants 5,420 RSUs to 21 new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633292560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633292560?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011285,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines granted restricted stock unit awards covering 5,420 common shares to 21 new non-executive employees on May 1, 2026.Awards were issued under Praxis 2024 Inducement Plan.Restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL6kfrPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE0009355771.USD","IE00BN0W2T93.GBP","IE0002141913.USD","LU0320765992.SGD","PRAX","SG9999014013.SGD","IE00BJT1NW94.SGD","BK4588","IE00B2B36J28.USD","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","LU0889565916.HKD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0109394709.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925506","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925506?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA7GDZLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","LU0889565916.HKD","IE00B2B36J28.USD","PRAX","LU0109394709.USD","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4139","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633512943","title":"Praxis Precision Medicines Inc  expected to post a loss of $3.57 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633512943","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633512943?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:48","pubTimestamp":1777985291,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc  expected to post a loss of $3.57 a share - Earnings Preview Praxis Precision Medicines Inc PRAX.OQ PRAX.O is expected to  show no change in quarterly revenue when it re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4139","LU0320765992.SGD","IE0002141913.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","PRAX","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633639769","title":"Praxis Precision Medicines updates financial calendar for first-quarter results and investor conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633639769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633639769?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924895,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines schedules Q1 2026 results release, corporate update, conference call at 8:30 a.m. ET on May 7, 2026; webcast via .Bank of America Securities Health Care Conference presentation set for May 12, 2026 at 7:20 p.m. EDT in Las Vegas; live webcast via .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8QQBFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B2B36J28.USD","BK4585","SG9999014021.USD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","IE0002141913.USD","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210149790.SGD","LU0320765992.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","PRAX","SG9999014039.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633668159","title":"Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633668159","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633668159?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924860,"startTime":"0","endTime":"0","summary":"857-702-9452. Media Contact:. Dan Ferry. Life Science Advisors. 617-430-7576","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287106/0/en/Praxis-Precision-Medicines-to-Report-First-Quarter-2026-Financial-Results-on-Thursday-May-7-2026-and-Participate-in-Upcoming-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","IE00BJJMRZ35.SGD","BK4200","LU0320765992.SGD","IE00B2B36J28.USD","IE0009355771.USD","LU0109394709.USD","PRAX","IE00BJT1NW94.SGD","BK4139","CNS","BK4135","LU0889565916.HKD","ASO","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.0327},{"period":"6month","weight":0.9618},{"period":"1year","weight":7.671},{"period":"ytd","weight":0.1197}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.017086},{"month":5,"riseRate":0.5,"avgChangeRate":-0.097568},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction